Gilmar Reis

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom et al. · The Lancet · 2017 · 855 citations · Full text

Thrombosis, Cardiovascular Disease, Stroke +13

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch et al. · The Lancet · 2017 · 749 citations · Full text

Thrombosis, Cardiovascular Disease, Atherosclerosis +12

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker et al. · The Lancet · 2020 · 723 citations · Full text

Heart Failure, Iron Metabolism, Clinical Nutrition +5

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10